Development of casein micellar pediatric formulations

Abstract

"The current need for medicines specifically designed for children, which consider ease of administration, dose flexibility, palatability, safety of excipients, stability and therapeutic equivalency of pediatric dosage forms, has driven the development of pediatric drug formulations. In the present work casein (CN) based micellar formulations are evaluated as vehicles for the oral delivery of pediatric drugs, since caseins are nontoxic, biodegradable, GRAS materials and nanoencapsulation of drugs can improve their bioavailability. Chemical crosslinking of casein by carbodiimide (EDC) has been studied as an approach to improve the stability of the CN micelles and to tailor drug release."